Biology-driven modality selection to manage risk and improve clinical relevance.
Our expertise spans small molecules, degraders, peptides and peptidomimetics, as well as biologics from mono- to multi-specific antibodies, enabling precision-driven intervention across complex disease biology.

Proven experience across diverse therapeutic areas including Oncology (immuno-oncology, targeted therapies), Immunology, and Infectious diseases.

Translating scientific value into investor-ready narratives
We support funding efforts across grants, non-dilutive mechanisms, and early investor engagement by aligning scientific strategy with realistic development and value-creation milestones.

Translating ideas into IND-ready assets
From target ideation to Phase 2 clinical support, seamlessly driving the drug discovery pipeline through biomarker discovery, hit identification, lead optimization, candidate selection, regulatory filings, and clinical development.

Flexible collaboration models to scale programs efficiently
Strategic collaborations with principal investigators, hospitals, and academic institutions, both within India and internationally, fueling innovation and translational impact.